drugset
drugset / Trial / NCT01018745

Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan

NCT01018745 ↗

Phase 1 Completed 3 enrolled Bristol-Myers Squibb
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical study is to establish the maximum tolerated dose (MTD) and recommended Phase 2 dose (or dose range as appropriate) of BMS-907351 (XL184) when administered orally on a once daily schedule in subjects with advanced or metastatic solid tumors.

Timeline

Start
2010-01
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Cabozantinib Small molecule 25 mg Oral
Subject Cabozantinib Small molecule 50 mg Oral
Subject Cabozantinib Small molecule 75 mg Oral
Subject Cabozantinib Small molecule 100 mg Oral
Subject Cabozantinib Small molecule 125 mg Oral
Subject Cabozantinib Small molecule 175 mg Oral

Indications

neoplasm